GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Itoco Inc (OTCPK:ITMC) » Definitions » Current Deferred Revenue

Itoco (ITMC) Current Deferred Revenue : $0.00 Mil (As of Sep. 2010)


View and export this data going back to 2009. Start your Free Trial

What is Itoco Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Itoco's current deferred revenue for the quarter that ended in Sep. 2010 was $0.00 Mil.

Itoco Current Deferred Revenue Historical Data

The historical data trend for Itoco's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Itoco Current Deferred Revenue Chart

Itoco Annual Data
Trend Dec08 Dec09
Current Deferred Revenue
- -

Itoco Quarterly Data
Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Itoco Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Itoco's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Itoco (ITMC) Business Description

Traded in Other Exchanges
N/A
Address
50 West Liberty Street, Suite 880, Reno, NV, USA, 89501
Itoco Inc is focused on developing and bringing biotech products to the market via co-development and joint venture arrangements with various companies. The company is currently examining various technologies that seek to control and/or identify bio-contaminants such as viruses and bacteria.